Floatz logo

Anti-Cd19/Cd22 Car-T Cells

Follicular Lymphoma ( FL)

First Affiliated Hospital Xi'an Jiaotong UniversityCell therapyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

209 Active assets in the Follicular Lymphoma ( FL) cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Anti-Cd19/Cd22 Car-T Cells is also rated in:

CAR T Cell TherapyDormant
B
Indicative ·
57 / 100
View asset →
Acute Lymphobkastic LeukemiaDormant
B
Indicative ·
57 / 100
View asset →
Auto Stem Cell TransplantDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →